Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Factors influencing the efficacy of rilpivirine in HIV-1 subtype C in low- and middle-income countries.

The Journal of antimicrobial chemotherapy - 1 Feb 2016

Neogi Ujjwal, Häggblom Amanda, Singh Kamalendra, Rogers Leonard C, Rao Shwetha D, Amogne Wondwossen, Schülter Eugen, Zazzi Maurizio, Arnold Eddy, Sarafianos Stefan G, Sönnerborg Anders

Abstract excerpt

OBJECTIVES: The use of the NNRTI rilpivirine in low- and middle-income countries (LMICs) is under debate. The main objective of this study was to provide further clinical insights and biochemical evidence on the usefulness of rilpivirine in LMICs. PATIENTS AND METHODS: Rilpivirine resistance was assessed in 5340 therapy-naive and 13,750 first-generation NNRTI-failed patients from Europe and therapy-naive HIV-1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Developing Countries

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ethiopia

Share to Europe

Share to HIV Reverse Transcriptase

Share to Inhibitory Concentration 50

Share to Rilpivirine

Share to Treatment Failure

Source

Open in PubMed Open full text

Identifiers

PMID: 26518047
DOI: 10.1093/jac/dkv359
PMCID: PMC4710214

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Factors influencing the efficacy of rilpivirine in HIV-1 subtype C in low- and middle-income countries.PMID 26518047Read ↗

Systematic review to determine the prevalence of transmitted drug resistance mutations to rilpivirine in HIV-infected treatment-naive persons.Semantic proximity Read ↗

Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countriesSemantic proximity Read ↗

E138A in HIV-1 reverse transcriptase is more common in subtype C than B: Implications for rilpivirine use in resource-limited settingsSemantic proximity Read ↗

Sub-Epidemics Explain Localized High Prevalence of Reduced Susceptibility to Rilpivirine in Treatment-Naive HIV-1-Infected Patients: Subtype and Geographic Compartmentalization of Baseline Resistance Mutations.Semantic proximity Read ↗

[Drug resistance characteristics of rilpivirine in HIV-1-infected patients before starting antiretroviral therapy in nine provinces of China].Semantic proximity Read ↗

Prevalence of genotypic baseline risk factors for cabotegravir + rilpivirine failure among ARV-naive patientsSemantic proximity Read ↗

Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.Semantic proximity Read ↗

Resistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection.Semantic proximity Read ↗

Transmitted drug resistance to rilpivirine among antiretroviral-naïve patients living with HIV from northern Poland.Semantic proximity Read ↗

Virological Failure on Long-Acting Injectable Cabotegravir and Rilpivirine: An Analysis of Subtypes, Drug Levels, Resistance, and Therapeutic Implications.Semantic proximity Read ↗

Selection of nonnucleoside reverse transcriptase inhibitor-associated mutations in HIV-1 subtype C: evidence of etravirine cross-resistance.Semantic proximity Read ↗

Phenotype, Genotype, and Drug Resistance in Subtype C HIV-1 Infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.